Arcellx, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACLX Nasdaq 2836 www.arcellx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcellx, Inc.

Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR‑T Program - Dec 23rd, 2025 5:14 pm
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls - Dec 22nd, 2025 7:47 am
Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More - Dec 22nd, 2025 6:12 am
Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight - Dec 11th, 2025 3:31 pm
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment - Dec 11th, 2025 5:44 am
Cancer Study Buoys These Small Biotechs - Dec 9th, 2025 1:31 pm
Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans - Dec 8th, 2025 12:07 am
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma - Dec 6th, 2025 12:00 pm
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Dec 6th, 2025 12:00 pm
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting - Nov 30th, 2025 3:42 am
Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition - Nov 18th, 2025 2:00 pm
How Investors Are Reacting To Arcellx (ACLX) Missing Revenue Estimates and Reporting Wider Losses - Nov 7th, 2025 1:10 pm
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 3:10 pm
Arcellx Provides Third Quarter 2025 Financial Results - Nov 5th, 2025 2:00 pm
Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates - Nov 4th, 2025 5:45 am
Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition - Nov 3rd, 2025 7:00 am
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Oct 30th, 2025 8:00 am
CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight - Oct 28th, 2025 3:31 pm
Why Arcellx (ACLX) Is Up 7.5% After Insider Sales and Optimism on CAR-T Regulatory Outlook - Oct 10th, 2025 2:12 am
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight - Oct 8th, 2025 11:00 am